Stem Cell-Derived Gene Expression Scores Predict Survival and Blastic Transformation in Myelofibrosis
Authors: Medeiros Jessie J.F. , Zeng Andy G.X. , Chan-Seng-Yue Michelle , Woo Tristan , Bansal Suraj , Kim Hyerin , McLeod Jessica L. , Arruda Andrea , Tsui Hubert , Claudio Jaime O. , Maze Dawn , Sibai Hassan , Minden Mark D. , Kennedy James A. , Wang Jean C.Y. , Dick John E. , Gupta Vikas 
Published: July 2024

Purpose

Myelofibrosis (MF) is the most severe myeloproliferative neoplasm (MPN) where there remains a need for improved risk stratification methods to better inform patient management. Since MF is a stem cell driven disease and stem cell informed transcriptomic information has been shown to be prognostic across other clinical settings we sought to use this information to generate novel transcriptomic-based risk stratification models that could complement current approaches.

Patients and Methods

We identified 358 MF patients from the MPN registry at the Princess Margaret Cancer Centre (ClinicalTrials.govIdentifier:NCT02760238) from whom peripheral blood mononuclear cells were collected and clinical data was available. We randomly split our cohort into a 250-patient training set and a 108-patient test set to train and validate prognostic models, respectively.

Results

Within the training set we used repeated nested cross validation together with LASSO regression from various starting gene sets and found that the best prognostic models were consistently derived from transcriptomic variation among MF stem cells. From this gene set we trained our final model, a 24-gene weighted expression score (termed, MPN24) that is prognostic for overall survival. Patients were classified as MPN24-High or MPN24-Low risk depending on whether their scores were above or below the within cohort median defined in the training set. The prognostic power of MPN24 was validated in the test set patients with stark differences in survival outcomes for MPN24-High (5-year survival rate = 21% [95% CI 9%-52%]) and MPN24-Low risk patients (5-year survival rate = 71% [95% CI 57-88%]) patients, resulting in a HR of 5.3 (95% CI: 2.6-10.5; p=2.08e-6). MPN24 captures unique prognostic information to current risk stratification models such as DIPSS, MIPSS70 and the Genomic-Personalized Risk scores. Therefore, we present a novel 3-tier risk stratification approach that integrates DIPSS and MPN24 to more effectively risk stratify MF patients, particularly via up or downscaling patient risk within the DIPSS-Intermediate-1/2 categories. In this integrated model patients were classified as Integrated-Low, Integrated-Intermediate or Integrated-High, and experienced 5-year survival rates of 88.2% [95% CI 77.9% - 99.9%], 39.3% [95% CI 19.9% - 77.7%], and 10.8% [95% CI 2.1% - 55.8%], respectively (likelihood ratio test p = 1e-8). Finally, from MPN24 genes we derived a 13-gene subsignature (termed, MPN13) from the training set patients that was validated to predict time-to-transformation in the test set patients when classified as MPN13-High or Low relative to the 80th percentile of MPN13 scores from the training set (p=0.0047). In the test set, MPN13-High and MPN13-Low patients experienced 3-year cumulative incidences of transformation of 5.2% [95% CI 0.2%-10.2%] and 28.6% [95% CI 3.1%-54.0%] respectively, after adjusting for death as a competing risk.

Conclusions

Transcriptomic information informed by MF stem cells offer novel and unique prognostic potential in MF that significantly complements current approaches. Future work will be needed to validate the robustness of the approach in external cohorts and identify how patient management can be optimized with these novel transcriptomic biomarkers.